Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  OTC Bulletin Board - Other OTC  >  Lixte Biotechnology Holdings, Inc.    LIXT

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

(LIXT)
SummaryQuotesChartsNewsCompany 
 News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news
Most relevant news about LIXTE BIOTECHNOLOGY HOLDIN
08/06The Spanish Sarcoma Group Will Lead a European Consortium to Evaluate the Abi..
GL
07/18First Patient Enrolled in Phase 1b/2 Trial of Lixte Biotechnology's LB-100 in..
GL
06/25Lixte Biotechnology's PP2A Inhibitor, LB-100, Improves Brain Function and Mot..
GL
05/15LIXTE BIOTECHNOLOGY : LB-100 to be Evaluated by the National Cancer Institute in..
AQ
2018LIXTE BIOTECHNOLOGY : FDA Approves Lixte Biotechnology's IND to Conduct a Phase ..
AQ
2018Lixte Biotechnology Files an IND with the FDA to Conduct a Phase 1b/2 Trial o..
GL
2018Lixte Biotechnology Announces a Clinical Trial Agreement with Moffitt Cancer ..
GL
2018LB-100 and LB-102, Lixte Biotechnology's Protein Phosphatase 2A Inhibitors, S..
GL
2017LIXTE BIOTECHNOLOGY : Protein Phosphatase 2A Inhibitor, LB-100, Reported to be a..
MW
2017LIXTE BIOTECHNOLOGY : Late-Breaking Abstract on LB-100, Lixte Biotechnology's Pr..
MW
2017LIXTE BIOTECHNOLOGY : First-In-Human Assessment of LB-100, Lixte Biotechnology's..
MW
2016LIXTE BIOTECHNOLOGY : Dr. Stephen Forman Joins Lixte Biotechnology's Board of Di..
MW
2016LIXTE BIOTECHNOLOGY : Lead Compound LB-100 Reported to Rapidly Improve Symptoms ..
MW
2016LIXTE BIOTECHNOLOGY : Completes Private Placement of Convertible Preferred Stock
MW
2009LIXTE BIOTECH HLDG : Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhanc..
PR
More most relevant news
All news about LIXTE BIOTECHNOLOGY HOLDIN
08/06LIXTE BIOTECHNOLOGY : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIO..
AQ
08/06LIXTE BIOTECHNOLOGY HOLDINGS, INC. : Entry into a Material Definitive Agreement,..
AQ
08/06The Spanish Sarcoma Group Will Lead a European Consortium to Evaluate the Abi..
GL
07/18First Patient Enrolled in Phase 1b/2 Trial of Lixte Biotechnology's LB-100 in..
GL
06/26LIXTE BIOTECHNOLOGY : Biotechnologys PP2A Inhibitor, LB-100, Improves Brain Func..
AQ
06/25Lixte Biotechnology's PP2A Inhibitor, LB-100, Improves Brain Function and Mot..
GL
05/17LIXTE BIOTECHNOLOGY : LB-100 to be Evaluated by the National Cancer Institute in..
AQ
05/15LIXTE BIOTECHNOLOGY : LB-100 to be Evaluated by the National Cancer Institute in..
AQ
05/09LIXTE BIOTECHNOLOGY : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIO..
AQ
03/25LIXTE BIOTECHNOLOGY : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIO..
AQ
More news
News in other languages on LIXTE BIOTECHNOLOGY HOLDIN

- No features available -

Press releases
08/06LIXTE BIOTECHNOLOGY : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIO..
AQ
08/06LIXTE BIOTECHNOLOGY HOLDINGS, INC. : Entry into a Material Definitive Agreement,..
AQ
08/06The Spanish Sarcoma Group Will Lead a European Consortium to Evaluate the Abi..
GL
07/18First Patient Enrolled in Phase 1b/2 Trial of Lixte Biotechnology's LB-100 in..
GL
06/26LIXTE BIOTECHNOLOGY : Biotechnologys PP2A Inhibitor, LB-100, Improves Brain Func..
AQ
More press releases
Sector news : Biotechnology & Medical Research - NEC
10/18GRAPHIC - TAKE FIVE : Super Saturday, Super Mario
RE
10/18TODAY'S LOGISTICS REPORT : Fred Smith's Growing FedEx Challenge; Seeking Rail Vo..
DJ
10/18JOHNSON & JOHNSON : Genmab, Janssen Get CHMP Positive Option for Expanded Darzal..
DJ
10/18SNAKES AND LADDERS : SoftBank Vision Fund's climbing, sliding valuations
RE
10/18European Businesses Give Draft Deal Cautious Welcome -- WSJ
DJ
More sector news : Biotechnology & Medical Research - NEC